Skip to main content
SpringerLink
Log in
Book cover

Molecular Aspects of Hematologic Malignancies pp 183–197Cite as

Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia

  • Chapter
  • First Online:

  • 1353 Accesses

Part of the book series: Principles and Practice ((PRINCIPLES))

Abstract

In recent years, significant progress has been achieved in the monitoring of treatment effectiveness in hematological malignancies through the detection of so-called minimal residual disease (MRD). In this chapter, we present the methodological principles of MRD monitoring and its clinical application using acute lymphoblastic leukemia as a model disease. Detection of MRD kinetics during the first months of treatment has high prognostic value and it is currently employed for patient stratification in many treatment protocols. In high-risk patients and relapsed patients the MRD clearance is a prerequisite for effective stem cell transplantation. Therefore, MRD monitoring forms the basis for subsequent treatment intervention.

Tomasz Szczepański and Małgorzata Dawidowska contributed equally.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A, Steward CG, Handgretinger R, Beck JF, Klingebiel T (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16(9):1668–1672

    Article  PubMed  CAS  Google Scholar 

  • Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 27(3):377–384. doi:10.1200/JCO.2008.17.6065, JCO.2008.17.6065[pii]

    Article  PubMed  Google Scholar 

  • Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A (2009) Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113(18):4153–4162. doi:10.1182/blood-2008-11-185132, blood-2008-11-185132[pii]

    Article  PubMed  CAS  Google Scholar 

  • Bene MC, Kaeda JS (2009) How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 94(8):1135–1150. doi:10.3324/haematol.2008.004267, haematol.2008.004267[pii]

    Article  PubMed  CAS  Google Scholar 

  • Biondi A, Valsecchi MG, Seriu T, D’Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grumayer ER (2000) Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM Study Group. Leukemia 14(11):1939–1943

    Article  PubMed  CAS  Google Scholar 

  • Braziel RM, Shipp MA, Feldman AL, Espina V, Winters M, Jaffe ES, Petricoin EF, 3rd, Liotta LA (2003) Molecular diagnostics. Hematol Am Soc Hematol Educ Program 2003(1):279–293

    Google Scholar 

  • Brisco J, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, Szer J, McCaul K, Morley AA (1996) Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 87(12):5251–5256

    PubMed  CAS  Google Scholar 

  • Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H et al (1994) Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343(8891):196–200

    Article  PubMed  CAS  Google Scholar 

  • Brown M, Wittwer C (2000) Flow cytometry: principles and clinical applications in hematology. Clin Chem 46(8 Pt 2):1221–1229

    PubMed  CAS  Google Scholar 

  • Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, Luschen S, Pott C, Ritgen M, Scheuring U, Horst HA, Thiel E, Hoelzer D, Bartram CR, Kneba M (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107(3):1116–1123. doi:10.1182/blood-2005-07-2708, 2005-07-2708[pii]

    Article  PubMed  Google Scholar 

  • Campana D (2009) Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin N Am 23(5):1083–1098, vii. doi:S0889-8588(09)00148-8, [pii] 10.1016/j.hoc.2009.07.010

  • Campana D (2010) Minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2010:7–12. doi:10.1182/asheducation-2010.1.7, 2010/1/7[pii]

    Article  Google Scholar 

  • Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer–Childhood Leukemia Cooperative Group. N Engl J Med 339(9):591–598

    Google Scholar 

  • Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, Arico M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115(16):3206–3214. doi:10.1182/blood-2009-10-248146, blood-2009-10-248146[pii]

    Article  PubMed  CAS  Google Scholar 

  • Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D (1998) Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351(9102):550–554. doi:10.1016/S0140-6736(97)10295-1, S0140-6736(97)10295-1[pii]

    Article  PubMed  CAS  Google Scholar 

  • Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Andreansky M, Hancock ML, Pui CH, Campana D (2004) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 18(3):499–504

    Article  PubMed  CAS  Google Scholar 

  • Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96(8):2691–2696

    PubMed  CAS  Google Scholar 

  • Dawidowska M, Jolkowska J, Szczepanski T, Derwich K, Wachowiak J, Witt M (2008) Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience. Arch Immunol Ther Exp (Warsz) 56(6):409–418. doi:10.1007/s00005-008-0045-y

    Article  Google Scholar 

  • Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, Fritsch G, Gadner H (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99(6):1952–1958

    Article  PubMed  CAS  Google Scholar 

  • Dworzak MN, Panzer-Grumayer ER (2003) Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma 44(9):1445–1455

    Article  PubMed  Google Scholar 

  • Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358(9289):1239–1241

    Article  PubMed  CAS  Google Scholar 

  • Elorza I, Palacio C, Dapena JL, Gallur L, de Toledo JS, de Heredia CD (2010) Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 95(6):936–941. doi:10.3324/haematol.2009.010843, haematol.2009.010843[pii]

    Article  PubMed  Google Scholar 

  • Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schafer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22(4):771–782

    Google Scholar 

  • Foroni L, Hoffbrand AV (2002) Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15(1):71–90. doi: 10.1053/beha.2002.0186, S1521692602901866[pii]

    Article  PubMed  CAS  Google Scholar 

  • Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 17(12):2318–2357

    Article  PubMed  CAS  Google Scholar 

  • Goulden NJ, Knechtli CJ, Garland RJ, Langlands K, Hancock JP, Potter MN, Steward CG, Oakhill A (1998) Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 100(1):235–244

    Article  PubMed  CAS  Google Scholar 

  • Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van Dongen JJ, Szczepanski T (2002) Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program :162–192

    Google Scholar 

  • Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Krol M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A (2008) Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. doi:10.1111/j.1365-2141.2008.07185.x, BJH7185 [pii]

  • Jółkowska J, Derwich K, Dawidowska M (2007) Methods of minimal residual disease (MRD) detection in childhood haematological malignancies. J Appl Genet 48(1):77–83

    Article  PubMed  Google Scholar 

  • Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, Böttcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonça A, de Tute R, Cullen M, Sedek L, Vidriales MB, Pérez JJ, Mejstrikova E, Hrusak O, Szczepański T, van Dongen JJM, Orfao A (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia (in press)

    Google Scholar 

  • Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel PG, Muller I, Niethammer D, Bader P (2005) Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 128(6):774–782. doi:10.1111/j.1365-2141.2005.05401.x, BJH5401[pii]

    Article  PubMed  CAS  Google Scholar 

  • Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M (2010) Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int J Hematol 92(3):481–489. doi:10.1007/s12185-010-0670-1

    Article  PubMed  CAS  Google Scholar 

  • Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, Jones CG, Rowbottom AW, Hunt LP, Green AF, Clarke E, Lankester AW, Cornish JM, Pamphilon DH, Steward CG, Oakhill A (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92(11):4072–4079

    PubMed  CAS  Google Scholar 

  • Kraszewska MD, Dawidowska M, Kosmalska M, Sedek L, Grzeszczak W, Szczepanski T, Witt M (2012) Immunoglobulin/T-cell receptor gene rearrangements in the diagnostic paradigm of pediatric T-cell acute lymphoblastic leukemia patients. Leuk Lymphoma. doi:10.3109/10428194.2011.654338

    PubMed  Google Scholar 

  • Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ (1997) Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 11(12):2192–2199

    Article  PubMed  CAS  Google Scholar 

  • Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Revesz T, van Dongen JJ, van der Velden VH, Schilham MW (2010) Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 24(8):1462–1469. doi:10.1038/leu.2010.133, leu2010133[pii]

    Article  PubMed  CAS  Google Scholar 

  • Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T, Bjorklund E, Biondi A, van den Beemd MW, Baars E, Vidriales B, Parreira A, van Dongen JJ, San Miguel JF, Orfao A (2001) BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: International Standardization and Clinical Evaluation. Leukemia 15(8):1185–1192

    Google Scholar 

  • Malec M, van der Velden VH, Bjorklund E, Wijkhuijs JM, Soderhall S, Mazur J, Bjorkholm M, Porwit-MacDonald A (2004) Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 18(10):1630–1636

    Article  PubMed  CAS  Google Scholar 

  • Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cave H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grumayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Moricke A, Schrappe M, Alonso CN, Schafer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R (2009) New insights to the MLL recombinome of acute leukemias. Leukemia 23(8):1490–1499. doi:10.1038/leu.2009.33, leu200933[pii]

    Article  PubMed  CAS  Google Scholar 

  • Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, Prentice HG, Goldstone A, Hoffbrand AV, Foroni L (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20(4):1094–1104

    Article  PubMed  Google Scholar 

  • Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, Campana D (2004) Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 18(5):934–938

    Article  PubMed  CAS  Google Scholar 

  • Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, Wesenberg F, Jonsson OG, Forestier E, Schmiegelow K (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99(4):1253–1258

    Article  PubMed  CAS  Google Scholar 

  • Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H (2000) Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95(3):790–794

    PubMed  CAS  Google Scholar 

  • Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grumayer ER, Biondi A, San Miguel JF, van Dongen JJ (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13(1):110–118

    Article  PubMed  CAS  Google Scholar 

  • Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12(12):2006–2014

    Article  PubMed  CAS  Google Scholar 

  • Pulsipher MA, Bader P, Klingebiel T, Cooper LJ (2009) Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 15(1 Suppl):62–71. doi:10.1016/j.bbmt.2008.11.009, S1083-8791(08)00489-8[pii]

    Article  PubMed  Google Scholar 

  • Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S, Bottcher S, Horst HA, Kneba M, Hoelzer D, Bruggemann M (2007) Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109(3):910–915. doi:10.1182/blood-2006-07-037093, blood-2006-07-037093[pii]

    Article  PubMed  CAS  Google Scholar 

  • Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, Taskinen M (2010) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24(2):345–354. doi:10.1038/leu.2009.251, leu2009251[pii]

    Article  PubMed  CAS  Google Scholar 

  • Szczepański T (2007) Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 21(4):622–626

    PubMed  Google Scholar 

  • Szczepański T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJM (2001) Minimal residual disease in leukaemia patients. Lancet Oncol 2(7):409–417

    Article  PubMed  Google Scholar 

  • Szczepański T, van der Velden VHJ, van Dongen JJM (2002) Real-time quantitative (RQ)-PCR for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Haematologica 87S1:183–191

    Google Scholar 

  • Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O (2001) The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 98(6):1982–1984

    Article  PubMed  CAS  Google Scholar 

  • van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ (2007a) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4):604–611

    PubMed  Google Scholar 

  • Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grumayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ (2009) Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 23(6):1073–1079. doi:10.1038/leu.2009.17, leu200917[pii]

    Article  PubMed  Google Scholar 

  • van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17(6):1013–1034

    Article  PubMed  Google Scholar 

  • van der Velden VH, Joosten SA, Willemse MJ, van Wering ER, Lankester AW, van Dongen JJ, Hoogerbrugge PM (2001) Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 15(9):1485–1487

    Article  PubMed  Google Scholar 

  • van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ (2007b) Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21(4):706–713

    PubMed  Google Scholar 

  • van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12):2257–2317

    Article  PubMed  Google Scholar 

  • van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352(9142):1731–1738

    Article  PubMed  Google Scholar 

  • van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, van der Velden VHJ, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (in press)

    Google Scholar 

  • Vidriales MB, Perez JJ, Lopez-Berges MC, Gutierrez N, Ciudad J, Lucio P, Vazquez L, Garcia-Sanz R, del Canizo MC, Fernandez-Calvo J, Ramos F, Rodriguez MJ, Calmuntia MJ, Porwith A, Orfao A, San-Miguel JF (2003) Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 101(12):4695–4700. doi:10.1182/blood-2002-08-2613, 2002-08-2613[pii]

    Google Scholar 

  • Yamaji K, Okamoto T, Yokota S, Watanabe A, Horikoshi Y, Asami K, Kikuta A, Hyakuna N, Saikawa Y, Ueyama J, Watanabe T, Okada M, Taga T, Kanegane H, Kogawa K, Chin M, Iwai A, Matsushita T, Shimomura Y, Hori T, Tsurusawa M (2010) Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 55(7):1287–1295. doi:10.1002/pbc.22620

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This chapter was partly supported by the Ministry of Science and Higher Education, grant N N407 311 839.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology and Oncology, Medical University of Silesia, 3 Maja 13/15, 41-800, Zabrze, Poland

    Tomasz Szczepański

  2. Department of Molecular and Clinical Genetics, Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479, Poznań, Poland

    Małgorzata Dawidowska

  3. Department of Pediatric Oncology, Hematology and Transplantology, Poznań University of Medical Sciences, Szpitalna 27/33, 60-572, Poznań, Poland

    Katarzyna Derwich

Authors
  1. Tomasz Szczepański
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Małgorzata Dawidowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katarzyna Derwich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomasz Szczepański .

Editor information

Editors and Affiliations

  1. International Institute of Molecular and, Trojdena 4, Warszawa, 02-109, Poland

    Michal Witt

  2. , Institute of Human Genetics, Polish Academy of Sciences, ul. Strzeszynska 32, Poznan, 60479, Poland

    Malgorzata Dawidowska

  3. , Department of Pediatric Hematology, Silesian Academy of Medicine, 3 Maja 13-15, Zabrze, 41800, Poland

    Tomasz Szczepanski

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Szczepański, T., Dawidowska, M., Derwich, K. (2012). Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia. In: Witt, M., Dawidowska, M., Szczepanski, T. (eds) Molecular Aspects of Hematologic Malignancies. Principles and Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29467-9_11

Download citation

Publish with us

Policies and ethics

Search

Navigation